Abstract: This disclosure relates to the use of certain diaryl macrocycle compounds, specifically (7S13R)-11-fluoro-7,13-di-methyl-6,7,13,14-tetrahydro-1,15-ethenopyrazolo[4,3-f][1,4,8,10]benzoxatriazacyclotridecin-4(5H)-one in the treatment of disease in mammals. This disclosure also relates to compositions including such compounds, and to methods of using such compositions in the treatment of diseases in mammals, especially in humans.

Abstract: The present disclosure relates to certain macrocyclic compounds that inhibit SRC and MET, and/or CSF1R, pharmaceutical compositions containing such compounds, and methods of using such compounds to treat cancer.

Abstract: An irrigation system that controls the irrigation operations based upon soil irrigation decisions and weather forecasts generated by specific meteorological data, including soil temperature, soil moisture, air temperature, air humidity, air pressure, and rainfall collected by different sensors. The system comprises an irrigation decision module, a soil decision module, an air factor decision module, a rainfall information sensor, an irrigation controller, and a mobile APP. The irrigation system uses low-power radio frequency networking technology to communicate between different modules and devices.

Abstract: This disclosure relates to the use of certain diaryl macrocycle compounds, specifically (7S13R)-11-fluoro-7,13-di-methyl-6,7,13,14-tetrahydro-1,15-ethenopyrazolo[4,3-f][1,4,8,10]benzoxatriazacyclotridecin-4(5H)-one in the treatment of disease in mammals. This disclosure also relates to compositions including such compounds, and to methods of using such compositions in the treatment of diseases in mammals, especially in humans.

Abstract: The present disclosure relates to certain macrocyclic compounds that inhibit SRC and MET, and/or CSF1R, pharmaceutical compositions containing such compounds, and methods of using such compounds to treat cancer.

Abstract: The present disclosure relates to certain macrocyclic compounds that inhibit SRC and MET, and/or CSF1R, pharmaceutical compositions containing such compounds, and methods of using such compounds to treat cancer.

Abstract: The present disclosure relates to certain macrocyclic compounds that inhibit SRC and MET, and/or CSF1R, pharmaceutical compositions containing such compounds, and methods of using such compounds to treat cancer.

Abstract: The present invention provides a method and a device for iris recognition. By providing a sensing unit under the iris recognition region of the display unit, the invention can capture the iris information of the user's eyeball in time, and then compare with the presetting iris information, and execute the operation instruction corresponding to the iris information, thereby effectively improving the precision of the iris recognition. In addition, the sensing unit is disposed under the display unit, and the overall thickness of the mobile device can be effectively reduced compared with the structure in which the camera is protruded and disposed independently outside the region of the display screen, so that the wearable device or the mobile device is thinner and more suitable for flexible wearable devices or mobile devices, to meet the needs of the market.

Abstract: This disclosure relates to the use of certain diaryl macrocycle compounds, specifically (7S13R)-11-fluoro-7,13-di-methyl-6,7,13,14-tetrahydro-1,15-ethenopyrazolo[4,3-f][1,4,8,10]benzoxatriazacyclotridecin-4(5H)-one in the treatment of disease in mammals. This disclosure also relates to compositions including such compounds, and to methods of using such compositions in the treatment of diseases in mammals, especially in humans.

Abstract: Disclosed are a permanent magnet linear motor and a linear vibrator, the linear vibrator includes the permanent magnet linear motor, the permanent magnet linear motor includes a stator component, a rotor component and a motor housing (6), the stator component and the rotor component are both mounted in the motor housing (6), the rotor component includes a shaft (1), a supporter (9), and a permanent magnet (2), the supporter (9) is fixedly defined at the middle part of the shaft (1), the permanent magnet (2) is fixedly embedded in the supporter (9); the stator component includes a stator core (4), a frame (11), and a coil winding (8), the stator core (4) is fixedly defined in the motor housing (6), the frame (11) is formed by defining tooth structure on the stator core (4) along a radial direction, the coil winding (8) is coiled on the frame (11).

Abstract: The present disclosure relates to certain macrocyclic compounds that inhibit SRC and MET, and/or CSF1R, pharmaceutical compositions containing such compounds, and methods of using such compounds to treat cancer.

Abstract: Disclosed are a permanent magnet linear motor and a linear vibrator, the linear vibrator includes the permanent magnet linear motor, the permanent magnet linear motor includes a stator component, a rotor component and a motor housing (6), the stator component and the rotor component are both mounted in the motor housing (6), the rotor component includes a shaft (1), a supporter (9), and a permanent magnet (2), the supporter (9) is fixedly defined at the middle part of the shaft (1), the permanent magnet (2) is fixedly embedded in the supporter (9); the stator component includes a stator core (4), a frame (11), and a coil winding (8), the stator core (4) is fixedly defined in the motor housing (6), the frame (11) is formed by defining tooth structure on the stator core (4) along a radial direction, the coil winding (8) is coiled on the frame (11).

Abstract: This disclosure relates to the use of certain diaryl macrocycle compounds, specifically (7S13R)-11-fluoro-7,13-di-methyl-6,7,13,14-tetrahydro-1,15-ethenopyrazolo [4,3-f][1,4,8,10]benzoxatriazacyclotridecin-4(5H)-one in the treatment of disease in mammals. This disclosure also relates to compositions including such compounds, and to methods of using such compositions in the treatment of diseases in mammals, especially in humans.